Small-Cell Lung Cancer - Pipeline Review, H1 2013


#164360

223pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, 'Small-Cell Lung Cancer - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Small-Cell Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer. 

Small-Cell Lung Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Small-Cell Lung Cancer.
  • A review of the Small-Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Small-Cell Lung Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Small-Cell Lung Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Small-Cell Lung Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 8
Global Markets Direct Report Coverage 8
Small-Cell Lung Cancer Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Small-Cell Lung Cancer 10
Small-Cell Lung Cancer Therapeutics under Development by Companies 12
Small-Cell Lung Cancer Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Discovery and Pre-Clinical Stage Products 22
Comparative Analysis 22
Small-Cell Lung Cancer Therapeutics - Products under Development by Companies 23
Small-Cell Lung Cancer Therapeutics - Products under Investigation by Universities/Institutes 27
Companies Involved in Small-Cell Lung Cancer Therapeutics Development 29
Bristol-Myers Squibb Company 29
Amgen Inc. 30
Sanofi-Aventis 31
Eli Lilly and Company 32
Dainippon Sumitomo Pharma Co., Ltd. 33
ZIOPHARM Oncology, Inc. 34
Millennium Pharmaceuticals, Inc. 35
Chong Kun Dang Pharmaceutical 36
ImmunoGen, Inc. 37
Nippon Kayaku Co., Ltd. 38
Teva Pharmaceutical Industries Limited 39
Exelixis, Inc. 40
Celgene Corporation 41
Bayer AG 42
4SC AG 43
Alchemia Limited 44
Hana Biosciences, Inc. 45
ImmunoCellular Therapeutics, Ltd. 46
Critical Outcome Technologies Inc. 47
Synta Pharmaceuticals Corp. 48
Simcere Pharmaceutical Group 49
MabVax Therapeutics, Inc. 50
Celator Pharmaceuticals, Inc. 51
Ascenta Therapeutics, Inc. 52
Cerulean Pharma, Inc. 53
Merrimack Pharmaceuticals, Inc. 54
Neotropix, Inc. 55
Innogene Kalbiotech Pte Ltd. 56
Mycenax Biotech Inc. 57
Polaris Group 58
CellAct Pharma GmbH 59
Small-Cell Lung Cancer - Therapeutics Assessment 60
Assessment by Monotherapy Products 60
Assessment by Combination Products 61
Assessment by Route of Administration 62
Assessment by Molecule Type 64
Drug Profiles 67
ipilimumab - Drug Profile 67
navitoclax - Drug Profile 69
alisertib - Drug Profile 71
lorvotuzumab mertansine - Drug Profile 73
irinotecan hydrochloride - Drug Profile 76
topotecan hydrochloride - Drug Profile 78
amrubicin hydrochloride - Drug Profile 79
amrubicin hydrochloride - Drug Profile 81
NTX-010 - Drug Profile 83
ICT-109 - Drug Profile 85
cabozantinib - Drug Profile 87
COTI-2 - Drug Profile 89
litronesib - Drug Profile 90
ganetespib - Drug Profile 92
Racotumomab - Drug Profile 95
irinotecan hydrochloride - Drug Profile 96
palifosfamide Intravenous - Drug Profile 98
CST-101 - Drug Profile 99
CRLX-101 - Drug Profile 100
Ektomun - Drug Profile 102
MDX-1110 - Drug Profile 103
ABT-737 - Drug Profile 104
imatinib mesylate + [irinotecan hydrochloride] + [cisplatin] - Drug Profile 105
chloroquine - Drug Profile 107
Docetaxel + Gemcitabine + Cisplatin + Vinorelbine + Pemetrexed - Drug Profile 108
belotecan hydrochloride + [cisplatin] - Drug Profile 109
Ad.p53-DC Vaccines + [paclitaxel] + [tretinoin] - Drug Profile 110
pravastatin sodium + [carboplatin] + [etoposide] - Drug Profile 111
ipilimumab + [carboplatin] + [paclitaxel] - Drug Profile 113
ADI-PEG 20 - Drug Profile 115
NK-012 - Drug Profile 118
ganitumab + [cisplatin] + [etoposide] - Drug Profile 120
ganitumab + [carboplatin] + [etoposide] - Drug Profile 121
obatoclax mesylate + [carboplatin] + [etoposide] - Drug Profile 123
Endostatin + [carboplatin] + [etoposide] - Drug Profile 124
Docetaxel + Bevacizumab - Drug Profile 125
BMS-833923 + [carboplatin] + [etoposide phosphate] - Drug Profile 126
amrubicin hydrochloride + [cisplatin] - Drug Profile 127
cixutumumab + [cisplatin] + [etoposide] - Drug Profile 128
bevacizumab + [cisplatin] + [irinotecan hydrochloride hydrochloride] - Drug Profile 129
sunitinib malate + [carboplatin] + [etoposide] - Drug Profile 130
icelecoxib + [decitabine] + [depsipeptide] - Drug Profile 132
AT-101 + [topotecan hydrochloride] - Drug Profile 134
bendamustine hydrochloride - Drug Profile 135
nogitecan - Drug Profile 136
cabazitaxel - Drug Profile 137
tirapazamine + [cisplatin] + [etoposide] - Drug Profile 138
belinostat + [cisplatin] + [etoposide] - Drug Profile 139
Autologous Dendritic Cell Adenovirus P53 Vaccine + [carboplatin] + [etoposide] + [tretinoin] - Drug Profile 140
Autologous Dendritic Cell Adenovirus P53 Vaccine + [carboplatin] + [etoposide] - Drug Profile 142
Adva-27a - Drug Profile 144
COTI-219 - Drug Profile 146
COTI-4A - Drug Profile 147
COTI-58 - Drug Profile 148
lorvotuzumab mertansine + [carboplatin] + [etoposide] - Drug Profile 149
irinotecan hydrochloride + cisplatin - Drug Profile 150
bemiparin - Drug Profile 152
ipilimumab + [carboplatin] + [etoposide] - Drug Profile 154
belotecan hydrochloride - Drug Profile 155
pomalidomide + [cisplatin] + [etoposide] - Drug Profile 156
belotecan hydrochloride - Drug Profile 157
navitoclax + [cisplatin] + [etoposide] - Drug Profile 158
linsitinib - Drug Profile 159
Drugs For Small Cell Lung Cancer - Drug Profile 160
r5B1 - Drug Profile 161
Small Cell Lung Cancer Vaccine - Drug Profile 162
nintedanib - Drug Profile 164
Therapeutic Antibodies For Small Cell Lung Cancer - Drug Profile 165
ipilimumab + [carboplatin] + [cisplatin] + [etoposide] - Drug Profile 166
Hedgehog Inhibitors - Drug Profile 167
CAP-7.1 - Drug Profile 168
bevacizumab Biosimilar - Drug Profile 170
EDC-7 - Drug Profile 171
Small-Cell Lung Cancer Therapeutics - Drug Profile Updates 172
Small-Cell Lung Cancer Therapeutics - Discontinued Products 205
Small-Cell Lung Cancer Therapeutics - Dormant Products 206
Small-Cell Lung Cancer - Product Development Milestones 210
Featured News & Press Releases 210

Appendix 217
Methodology 217
Coverage 217
Secondary Research 217
Primary Research 217
Expert Panel Validation 217
Contact Us 218
Disclaimer 218

Number of Products Under Development for Small-Cell Lung Cancer, H1 2013 15
Products under Development for Small-Cell Lung Cancer - Comparative Analysis, H1 2013 16
Number of Products under Development by Companies, H1 2013 18
Number of Products under Development by Companies, H1 2013 (Contd..1) 19
Number of Products under Development by Companies, H1 2013 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H1 2013 22
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 23
Comparative Analysis by Late Stage Development, H1 2013 24
Comparative Analysis by Mid Clinical Stage Development, H1 2013 25
Comparative Analysis by Early Clinical Stage Development, H1 2013 26
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 27
Products under Development by Companies, H1 2013 28
Products under Development by Companies, H1 2013 (Contd..1) 29
Products under Development by Companies, H1 2013 (Contd..2) 30
Products under Development by Companies, H1 2013 (Contd..3) 31
Products under Investigation by Universities/Institutes, H1 2013 32
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 33
Bristol-Myers Squibb Company, H1 2013 34
Amgen Inc., H1 2013 35
Sanofi-Aventis, H1 2013 36
Eli Lilly and Company, H1 2013 37
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 38
ZIOPHARM Oncology, Inc., H1 2013 39
Millennium Pharmaceuticals, Inc., H1 2013 40
Chong Kun Dang Pharmaceutical, H1 2013 41
ImmunoGen, Inc., H1 2013 42
Nippon Kayaku Co., Ltd., H1 2013 43
Teva Pharmaceutical Industries Limited, H1 2013 44
Exelixis, Inc., H1 2013 45
Celgene Corporation, H1 2013 46
Bayer AG, H1 2013 47
4SC AG, H1 2013 48
Alchemia Limited, H1 2013 49
Hana Biosciences, Inc., H1 2013 50
ImmunoCellular Therapeutics, Ltd., H1 2013 51
Critical Outcome Technologies Inc., H1 2013 52
Synta Pharmaceuticals Corp., H1 2013 53
Simcere Pharmaceutical Group, H1 2013 54
MabVax Therapeutics, Inc., H1 2013 55
Celator Pharmaceuticals, Inc., H1 2013 56
Ascenta Therapeutics, Inc., H1 2013 57
Cerulean Pharma, Inc., H1 2013 58
Merrimack Pharmaceuticals, Inc., H1 2013 59
Neotropix, Inc., H1 2013 60
Innogene Kalbiotech Pte Ltd., H1 2013 61
Mycenax Biotech Inc., H1 2013 62
Polaris Group, H1 2013 63
CellAct Pharma GmbH, H1 2013 64
Assessment by Monotherapy Products, H1 2013 65
Assessment by Combination Products, H1 2013 66
Assessment by Stage and Route of Administration, H1 2013 68
Assessment by Stage and Molecule Type, H1 2013 71
Small-Cell Lung Cancer Therapeutics - Drug Profile Updates 177
Small-Cell Lung Cancer Therapeutics - Discontinued Products 210
Small-Cell Lung Cancer Therapeutics - Dormant Products 211
Small-Cell Lung Cancer Therapeutics - Dormant Products (Contd..1) 212
Small-Cell Lung Cancer Therapeutics - Dormant Products (Contd..2) 213
Small-Cell Lung Cancer Therapeutics - Dormant Products (Contd..3) 214
Number of Products under Development for Small-Cell Lung Cancer, H1 2013 15
Products under Development for Small-Cell Lung Cancer - Comparative Analysis, H1 2013 16
Products under Development by Companies, H1 2013 17
Products under Investigation by Universities/Institutes, H1 2013 21
Late Stage Products, H1 2013 24
Mid Clinical Stage Products, H1 2013 25
Early Clinical Stage Products, H1 2013 26
Discovery and Pre-Clinical Stage Products, H1 2013 27
Assessment by Monotherapy Products, H1 2013 65
Assessment by Combination Products, H1 2013 66
Assessment by Route of Administration, H1 2013 67
Assessment by Stage and Route of Administration, H1 2013 68
Assessment by Molecule Type, H1 2013 69
Assessment by Stage and Molecule Type, H1 2013 70